Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
2.

CRISPR-UMI: single-cell lineage tracing of pooled CRISPR-Cas9 screens.

Michlits G, Hubmann M, Wu SH, Vainorius G, Budusan E, Zhuk S, Burkard TR, Novatchkova M, Aichinger M, Lu Y, Reece-Hoyes J, Nitsch R, Schramek D, Hoepfner D, Elling U.

Nat Methods. 2017 Dec;14(12):1191-1197. doi: 10.1038/nmeth.4466. Epub 2017 Oct 16.

PMID:
29039415
3.

Translation from unconventional 5' start sites drives tumour initiation.

Sendoel A, Dunn JG, Rodriguez EH, Naik S, Gomez NC, Hurwitz B, Levorse J, Dill BD, Schramek D, Molina H, Weissman JS, Fuchs E.

Nature. 2017 Jan 26;541(7638):494-499. doi: 10.1038/nature21036. Epub 2017 Jan 11.

4.

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM.

Oncotarget. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013.

5.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

6.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S.

Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8.

PMID:
27392790
7.

RANKL/RANK control Brca1 mutation-driven mammary tumors.

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.

Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

8.

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.

Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H.

Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Epub 2016 Mar 18. Erratum in: Cancer. 2016 Oct 15;122(20):3246.

9.

ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas.

Yang H, Schramek D, Adam RC, Keyes BE, Wang P, Zheng D, Fuchs E.

Elife. 2015 Nov 21;4:e10870. doi: 10.7554/eLife.10870.

10.

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.

11.

MKK7 and ARF: new players in the DNA damage response scenery.

Kotsinas A, Papanagnou P, Galanos P, Schramek D, Townsend P, Penninger JM, Bartek J, Gorgoulis VG.

Cell Cycle. 2014;13(8):1227-36. doi: 10.4161/cc.28654. Epub 2014 Mar 26.

12.

A dual role for autophagy in a murine model of lung cancer.

Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, Sigl V, Aumayr K, Schmauss G, Fellner N, Handschuh S, Glösmann M, Pasierbek P, Schlederer M, Resch GP, Ma Y, Yang H, Popper H, Kenner L, Kroemer G, Penninger JM.

Nat Commun. 2014;5:3056. doi: 10.1038/ncomms4056.

PMID:
24445999
13.

Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.

Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E.

Science. 2014 Jan 17;343(6168):309-13. doi: 10.1126/science.1248627.

14.

Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells.

Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, Szwarc MM, Cho C, Lydon JP, Khokha R, Penninger JM, Ormandy CJ.

Development. 2013 Apr;140(7):1397-401. doi: 10.1242/dev.088948. Epub 2013 Mar 5.

15.

A mouse model to identify cooperating signaling pathways in cancer.

Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Müller M, Kolbe T, Rülicke T, Moriggl R, Kenner L, Stoiber D, Penninger JM, Popper H, Casanova E, Eferl R.

Nat Methods. 2012 Sep;9(9):897-900. doi: 10.1038/nmeth.2130. Epub 2012 Aug 5.

PMID:
22863881
16.

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3.

PMID:
22858987
17.

Forward and reverse genetics through derivation of haploid mouse embryonic stem cells.

Elling U, Taubenschmid J, Wirnsberger G, O'Malley R, Demers SP, Vanhaelen Q, Shukalyuk AI, Schmauss G, Schramek D, Schnuetgen F, von Melchner H, Ecker JR, Stanford WL, Zuber J, Stark A, Penninger JM.

Cell Stem Cell. 2011 Dec 2;9(6):563-74. doi: 10.1016/j.stem.2011.10.012.

18.

RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.

Schramek D, Sigl V, Penninger JM.

Trends Endocrinol Metab. 2011 May;22(5):188-94. doi: 10.1016/j.tem.2011.02.007. Epub 2011 Apr 4. Review.

PMID:
21470874
19.

RANKL/RANK-beyond bones.

Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM.

J Mol Med (Berl). 2011 Jul;89(7):647-56. doi: 10.1007/s00109-011-0749-z. Epub 2011 Mar 29. Review.

PMID:
21445556
20.

The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression.

Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, Neely GG, Zwick RH, Sigl V, Forni G, Serrano M, Gorgoulis VG, Penninger JM.

Nat Genet. 2011 Mar;43(3):212-9. doi: 10.1038/ng.767. Epub 2011 Feb 13.

PMID:
21317887
21.

A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene.

Neely GG, Hess A, Costigan M, Keene AC, Goulas S, Langeslag M, Griffin RS, Belfer I, Dai F, Smith SB, Diatchenko L, Gupta V, Xia CP, Amann S, Kreitz S, Heindl-Erdmann C, Wolz S, Ly CV, Arora S, Sarangi R, Dan D, Novatchkova M, Rosenzweig M, Gibson DG, Truong D, Schramek D, Zoranovic T, Cronin SJ, Angjeli B, Brune K, Dietzl G, Maixner W, Meixner A, Thomas W, Pospisilik JA, Alenius M, Kress M, Subramaniam S, Garrity PA, Bellen HJ, Woolf CJ, Penninger JM.

Cell. 2010 Nov 12;143(4):628-38. doi: 10.1016/j.cell.2010.09.047.

22.

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM.

Nature. 2010 Nov 4;468(7320):98-102. doi: 10.1038/nature09387. Epub 2010 Sep 29.

23.

Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs.

Murphy DJ, Renninger JP, Schramek D.

J Pharmacol Toxicol Methods. 2010 Jul-Aug;62(1):47-53. doi: 10.1016/j.vascn.2010.04.006. Epub 2010 May 8.

PMID:
20435149
24.

Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, van Zijl F, Schneller D, Esterbauer H, Egger G, Mair M, Kenner L, Mikulits W, Eferl R, Moriggl R, Penninger J, Trauner M, Casanova E.

Hepatology. 2010 Apr;51(4):1319-26. doi: 10.1002/hep.23469.

25.

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development.

Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, Sutherland RL, Daly RJ.

Int J Cancer. 2010 Sep 1;127(6):1486-92. doi: 10.1002/ijc.25172.

26.

Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate.

Pospisilik JA, Schramek D, Schnidar H, Cronin SJ, Nehme NT, Zhang X, Knauf C, Cani PD, Aumayr K, Todoric J, Bayer M, Haschemi A, Puviindran V, Tar K, Orthofer M, Neely GG, Dietzl G, Manoukian A, Funovics M, Prager G, Wagner O, Ferrandon D, Aberger F, Hui CC, Esterbauer H, Penninger JM.

Cell. 2010 Jan 8;140(1):148-60. doi: 10.1016/j.cell.2009.12.027.

27.

Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection.

Cronin SJ, Nehme NT, Limmer S, Liegeois S, Pospisilik JA, Schramek D, Leibbrandt A, Simoes Rde M, Gruber S, Puc U, Ebersberger I, Zoranovic T, Neely GG, von Haeseler A, Ferrandon D, Penninger JM.

Science. 2009 Jul 17;325(5938):340-3. doi: 10.1126/science.1173164. Epub 2009 Jun 11.

28.

Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Brummer T, Larance M, Herrera Abreu MT, Lyons RJ, Timpson P, Emmerich CH, Fleuren ED, Lehrbach GM, Schramek D, Guilhaus M, James DE, Daly RJ.

EMBO J. 2008 Sep 3;27(17):2305-16.

29.

Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein.

Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA, Daly RJ.

J Biol Chem. 2006 Jan 6;281(1):626-37. Epub 2005 Oct 27.

30.

Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor.

Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ.

Cancer Res. 2005 Apr 15;65(8):3273-80.

Supplemental Content

Loading ...
Support Center